Achievement of On‑Treatment Remission With Risankizumab in Patients With Moderate‑to‑Severe Psoriasis

Main Article Content

April W. Armstrong
Department of Dermatology, Keck School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

Tiago Torres
Department of Dermatology, Centro Hospitalar Universitário de Sto António, University of Porto, Porto, Portugal

Joseph F. Merola
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA

Brian Kirby
The Charles Centre, Department of Dermatology, St. Vincent’s University Hospital, Dublin, Ireland; & School of Health Sciences and Charles Institute, University College Dublin, Dublin, Ireland;

Mark G. Lebwohl
Icahn School of Medicine at Mount Sinai, New York, NY, USA

Tshepiso Madihlaba
AbbVie Inc., North Chicago, IL, USA

Blair Kaplan
AbbVie Inc., North Chicago, IL, USA

Richard Ta
AbbVie Inc., North Chicago, IL, USA

Cuiyong Yue
AbbVie Inc., North Chicago, IL, USA

Deepak M.W. Balak
Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands

Richard B. Warren
Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR BRC, University of Manchester, Manchester, UK

Keywords

moderate-to-severe psoriasis, psoriasis

References

1. Armstrong AW, et al. J Eur Acad Dermatol Venereol. 2022;36:2291–300.

2. Papp KA, et al. Am J Clin Dermatol. 2025 Jul 29. doi.org/10.1007/s40257-025-00964-6. Online ahead of print.

3. Papp KA, et al. Br J Dermatol. 2021;185:1135–45.

4. Warren RB, et al. Br J Dermatol. 2001;184:3–4.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/1ahmv830

Article Details

How to Cite
1.
Achievement of On‑Treatment Remission With Risankizumab in Patients With Moderate‑to‑Severe Psoriasis. J of Skin. 2025;9(6):s653. doi:10.25251/1ahmv830
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>